… CCR7, effector T cells recruited via CXCR3/CCR5/CCR2/CCR6, mono… For instance, tumors
frequently exploit checkpoint pathways … infiltration of adoptive cell therapies to these cancers. …

… The early use of immune therapies (Interleukin-2 (IL-2), etc.) … and overexpression of
CXCR3/CCR5 chemokine ligands in … metastatic melanoma patients enrolled in adoptive therapy …

… molecular pathways involved in angiogenesis in melanoma … worse prognosis of melanoma
patients presenting with his … inhibitors [181] and adoptive cell therapy [182]. Interestingly, the …

… In conclusion, among cancer patients treated with immune checkpoint inhibitors, irAEs may
be more common among those exhibiting immune dysregulation. Specifically, cases with …

… the therapeutic target of the PI3K/AKT/mTOR signaling pathway dose not merely attenuates
tumor malignancy and metastasis… In the context of adoptive T cell therapy, TILs activation and …

… pathway may represent a viable therapeutic pathway in … monotherapy in patients with
advanced metastatic melanoma, … in a majority of treated-patient CTL signature gene expression …

… affect immune system pathways, could … patients. The same CCR5 polymorphism was found
to be associated with improved outcomes in both melanoma (in response to adoptive therapy…

… of conventional prognostic signatures adopted in breast cancer.… -1 signaling, CXCR3/CCR5
chemokines, immune effectors … pathway-high (ES >cancer specific median ES) and pathway-…

… also reported in adoptive T-cell transfer models (44–46). In patients with melanoma or
colorectal carcinoma, the recruitment of immune cells through CXCR3/CCR5 ligands is critical for …

… CAR T cell therapy has revolutionized adoptive cell therapy and … the pathways behind
cytokines was not the solution for treating … and interleukin-2 in the immunotherapy of patients with …